EN DE

TaiDoc Technology Corporation (4736) Fair Value & Analysis

Healthcare · TW · Market cap 12.3B TWD

TT TaiDoc Technology Corporation 4736 · TW
Price130.50 TWD
Fair Value192.71 TWD
Upside+47.7%
Quality66/100
Watch TaiDoc Technology Corporation for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Highly profitable · 40.5% net margin
Low debt · generates free cash flow
3.85% dividend yield
Ranks above peers (13/14)
Wide moat 71/100
Evidence: High Range 110.60 TWD – 238.46 TWD Share as image

Fair value as of: Jul 23, 2026

From 25 valuation models · updated 18 days ago

Share price +3.6% over the past month.

A solid business, screening 48% undervalued on our models.

What matters now

  • Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality.
  • A fairly wide model range (110.60 TWD to 238.46 TWD) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

214.67 TWD 107.77 TWD Fair Value 192.71 TWD Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.

How to read this chart

60‑month range 107.77 TWD – 214.67 TWD · fair‑value band 110.60 TWD – 238.46 TWD · the 130.50 TWD price screens below the 192.71 TWD fair value. Dashed = 300-day average. As of Jul 23, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

TaiDoc Technology Corporation (4736) currently trades at 130.50 TWD, while our model-based Fair Value estimate is 192.71 TWD, implying the stock looks roughly 47.7% undervalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, TaiDoc Technology Corporation generated revenue of 4.3B TWD at a net margin of 40.5%. Revenue grew 10.0% year over year. It earns a return on equity of 19.2%. The balance sheet holds a net cash position of 910M TWD. Fundamentals as of Jul 23, 2026

Our scenario range runs from 110.60 TWD (bear case) to 238.46 TWD (bull case); at 130.50 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 5% below its 52-week high and 15% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at 48%, 4736 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 90.86 TWD 120.01 TWD 160.07 TWD 80
Residual Income 103.40 TWD 128.53 TWD 263.05 TWD 76
Rev-Margin DCF 100.55 TWD 147.12 TWD 197.35 TWD 74
All 25 models by family
DCF Models
FCF DCF 88.95 TWD 120.53 TWD 165.99 TWD 38
Owner Earnings 172.61 TWD 242.58 TWD 343.28 TWD 31
5Y Revenue Exit 100.55 TWD 146.76 TWD 204.21 TWD 39
5Y EBITDA Exit 113.81 TWD 170.51 TWD 234.37 TWD 41
5Y P/E Exit 186.79 TWD 301.22 TWD 416.80 TWD 38
10Y Revenue Exit 92.90 TWD 133.47 TWD 184.66 TWD 36
10Y EBITDA Exit 103.89 TWD 149.58 TWD 206.78 TWD 37
10Y P/E Exit 149.63 TWD 238.26 TWD 340.55 TWD 35
Earnings-Based
Graham-Dodd 104.26 TWD 255.45 TWD 330.59 TWD 54
PEG = 1.0 45.83 TWD 65.47 TWD 85.11 TWD 46
EPV 92.73 TWD 104.83 TWD 115.42 TWD 59
Dividend Discount
Gordon GGM 90.39 TWD 164.76 TWD 263.12 TWD 70
DDM Multi-Stage 90.39 TWD 135.86 TWD 185.47 TWD 61
Multiples
P/E Multiple 252.98 TWD 337.30 TWD 421.63 TWD 63
P/S Multiple 117.35 TWD 156.47 TWD 195.59 TWD 58
P/B Multiple 195.48 TWD 260.64 TWD 325.80 TWD 55
EV/EBIT 149.77 TWD 192.98 TWD 236.20 TWD 53
EV/EBITDA 142.91 TWD 183.84 TWD 224.77 TWD 54
EV/Revenue 112.66 TWD 152.31 TWD 191.97 TWD 43
Asset-Based
NCAV (Graham) 52.03 TWD 69.72 TWD 104.06 TWD 50
Growth DCF
Growth DCF 90.86 TWD 120.01 TWD 160.07 TWD 80
Rev-Margin DCF 100.55 TWD 147.12 TWD 197.35 TWD 74
Economic Profit
Residual Income 103.40 TWD 128.53 TWD 263.05 TWD 76
ROIC Compounder 92.73 TWD 105.16 TWD 123.19 TWD 72
Growth Earnings
Growth-Adj P/E 193.14 TWD 275.91 TWD 358.69 TWD 68

Widest divergence: Growth Earnings (275.91 TWD) versus Asset-Based (69.72 TWD). Highest evidence: Growth DCF (80).

Notify me when 4736 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 4.3B TWD
Revenue growth (YoY) +10.0%
Net margin 40.5%
Return on equity 19.2%
Free cash flow 602M TWD FY2025
P/E ratio 8.7
More key figures
Operating margin 25.4%
EPS (TTM) 15.01 TWD
Dividend yield 3.9%
EPS growth (YoY) -2.5%
Net cash 910M TWD FY2025

Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 66/100

Of which business quality 65 · Market factors (momentum, volatility) 63

Profitability 54
Margins and returns on capital today
Quality Growth 32
Are margins and returns improving?
Cashflow 51
Earnings quality: real cash, not paper profit
Fin. Strength 90
Balance sheet, leverage, solvency risk
Investment 92
Disciplined investing over empire-building
Low Volatility 96
Calm price path (market factor)
Momentum 43
Price trend over the last 3–12 months (market factor)
52W Momentum 59
Distance to the 52-week high (market factor)
Net Issuance 76
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

TaiDoc Technology Corporation manufactures and markets medical devices in Taiwan and internationally. The company offers In vitro diagnostics products, including multiple parameter monitoring systems, point of care testing devices, and lancet and lancing devices; vet health care products comprise blood glucose and calcium meters, and blood ketone meters; …

Full company description

TaiDoc Technology Corporation manufactures and markets medical devices in Taiwan and internationally. The company offers In vitro diagnostics products, including multiple parameter monitoring systems, point of care testing devices, and lancet and lancing devices; vet health care products comprise blood glucose and calcium meters, and blood ketone meters; and medical devices, such as nebulizers, thermometers, blood pressure monitors, vital sign monitors, and pulse oximeters. It also provides telehealth remote monitoring devices and smartphone applications; and Covid-19 antigen rapid test kits. In addition, the company offers services for regulatory professionals, as well as in the areas of clinical suggestions, engineering resources, and manufacturing systems. Further, the company provides various applications, including MyLink, ProCheck, Healthy Check, Healthy Check PRO, PCLink, and USB adapter driver. TaiDoc Technology Corporation was founded in 1998 and is headquartered in New Taipei City, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

TaiDoc Technology Corporation reported revenue of 4.2B TWD in FY2025 versus 6.5B TWD in FY2021, a compound −10.3%/yr. Reported net income was 1.4B TWD in FY2025, compounding −7.6%/yr from FY2021.

Growth Quality 40/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
4.2B TWD
Latest YoY
−9.4%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−24.1%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−6.6%
Avg. growth/yr (16Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+4.4%
Revenue −10.3%/yr
FY21 6.5B TWD
FY22 9.6B TWD
FY23 4.8B TWD
FY24 4.6B TWD
FY25 4.2B TWD
Net income −7.6%/yr
FY21 2.0B TWD
FY22 3.4B TWD
FY23 1.0B TWD
FY24 1.2B TWD
FY25 1.4B TWD
Character of growth · EPS growth decomposed (2014-2025) +9.4 % p.a.
Revenue per share +3.7 pp

of which total revenue +5.7 pp · buybacks/dilution −2.0 pp

EBIT margin +0.6 pp
Tax rate −0.2 pp
Residual (interest, one-offs) +5.2 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

Watch 4736: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "TaiDoc Technology Corporation Fair Value". https://www.fairvalue-calculator.com/stock/4736

Peer Group

Medical Devices · 352 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 66 · Top 25%
Fair Value upside +48% · Top 25%
Return on equity (TTM) 19% · Top 25%
Return on assets 5% · Above median
Net margin (TTM) 40% · Top 25%
Operating margin (TTM) 25% · Top 25%
Revenue growth 10% · Above median
Dividend yield (TTM) 3.9% · Top 25%
Debt / equity 0.02× · Lower than median

Valuation Multiples vs Medical Devices median · lower = cheaper

P/E (TTM) 8.7× · Cheaper than 75% of peers
P/B 1.25× · Cheaper than median
P/S (TTM) 2.85× · Pricier than median
P/FCF 0.6× · Cheaper than 75% of peers
EV/EBITDA 9.2× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 97 · sector 0
FUTURE 50 · sector 29
PAST 77 · sector 8
HEALTH 99 · sector 97
DIVIDEND 77 · sector 38

Insider activity: 30/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $100.68 $74.79 -26%
Stryker Corporation SYK $316.44 $186.28 -41%
Medtronic plc MDT $83.56 $65.57 -22%
Boston Scientific Corporation BSX $43.04 $38.44 -11%
Edwards Lifesciences Corporation EW $85.73 $41.02 -52%
Siemens Healthineers AG SHL €34.59 €33.87 -2%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥149.43 ¥147.63 -1%
Shanghai United Imaging Healthcare Co 688271 ¥109.00 ¥43.60 -60%
Demant A/S DEMANT kr 276.60 kr 161.17 -42%
Getinge AB GETIB kr 206.80 kr 192.14 -7%

Compare TaiDoc Technology Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is TaiDoc Technology Corporation (4736) overvalued or undervalued?
As of Jul 23, 2026, our model estimates a fair value of 192.71 TWD versus a price of 130.50 TWD, about +48% (undervalued).
What is the fair value of 4736?
Our model-based fair value for TaiDoc Technology Corporation is 192.71 TWD (as of Jul 23, 2026), built from audited fundamentals. The current price is 130.50 TWD.
What is the quality score of 4736?
TaiDoc Technology Corporation has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of TaiDoc Technology Corporation (4736)?
TaiDoc Technology Corporation reported trailing-twelve-month revenue of about 4.3B TWD (latest available figure, as of Jul 23, 2026).
What is the net profit margin of 4736?
The net profit margin of TaiDoc Technology Corporation is about 40.5%, meaning it keeps roughly 40.5% of revenue as net income. Based on the latest reported figures.
Does TaiDoc Technology Corporation pay a dividend?
TaiDoc Technology Corporation currently shows a dividend yield of about 4.02% relative to its recent price (as of Jul 23, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track TaiDoc Technology Corporation and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.